STOCK TITAN
  1. Home
  2. News
  3. MDRX

VERADIGM INC - MDRX STOCK NEWS

Welcome to our dedicated page for VERADIGM news (Ticker: MDRX), a resource for investors and traders seeking the latest updates and insights on VERADIGM stock.

Veradigm Inc. (NASDAQ: MDRX) is a prominent player in the healthcare information technology sector, dedicated to enhancing clinical, financial, and operational results through innovative IT solutions. The company's core business revolves around creating an expansive, open, and connected community of health, which bridges the gaps between people, places, and data. This connectivity is pivotal in empowering caregivers to make informed decisions and deliver superior care, ultimately leading to healthier populations.

Veradigm's comprehensive suite of solutions includes electronic health records (EHR), practice management systems, revenue cycle management, and patient engagement tools. These products are meticulously designed to streamline healthcare operations, improve patient outcomes, and navigate the evolving landscape of healthcare delivery.

Recently, Veradigm has faced significant changes. The company was replaced in the S&P SmallCap 600 by Sprinklr Inc. (NYSE: CXM) and was suspended from the NASDAQ Stock Market effective February 29, 2024, due to non-compliance with NASDAQ listing rules. Despite these challenges, Veradigm continues to innovate and adapt, focusing on delivering value through their cutting-edge technology solutions.

Veradigm's commitment to connectivity extends to their robust partnerships and collaborations. These alliances enhance their ability to offer integrated solutions that meet the dynamic needs of the healthcare sector. Veradigm's financial condition and strategic initiatives reflect their dedication to maintaining leadership in the healthcare IT domain.

For more details and the latest updates on Veradigm Inc., visit their official website or follow their social media channels on Twitter, YouTube, and their blog.

News

Veradigm Provides Update on its Financial Restatement Process

Rhea-AI Summary
Veradigm Inc. (NASDAQ: MDRX) expects to receive a delisting notice from Nasdaq due to delayed financial filings, plans to restore compliance, and adopts a limited duration stockholder rights plan. The plan aims to protect stockholders' interests and prevent creeping acquisitions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.54%
Tags
none
-
News

Veradigm to Highlight New EHR-Integrated Care Gap Alert Solution at ViVE 2024 Conference

Rhea-AI Summary
Veradigm Inc. (MDRX) debuts Veradigm Payer Insights solution at ViVE 2024 conference, delivering care gap alerts to providers within EHR systems. The solution aims to enhance patient care outcomes by addressing gaps in care delivery, highlighting the company's commitment to driving improved clinical and financial outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
none
-
News

Veradigm Reveals New Insights on the Prevalence of Cardiovascular Conditions in the U.S.

Rhea-AI Summary
Veradigm Inc. (NASDAQ: MDRX) released its inaugural Veradigm Insights Report: Cardiovascular Conditions in 2024, analyzing de-identified data for 53 million unique cardiovascular patients. The report reveals the South as having the highest rates of hypertension, coronary artery disease, and heart failure. Utilizing NLP on structured and unstructured data, the report provides insights on CVD prevalence across all 50 states and various demographics, aiding in patient management and early intervention.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.09%
Tags
none
News

Veradigm and American College of Cardiology Launch Influenza Vaccination Education Initiative to Improve Cardiovascular Health

Rhea-AI Summary
Veradigm Inc. (NASDAQ: MDRX) launches TRANSFORM VAX initiative to improve cardiovascular health through influenza vaccination education. The initiative aims to reduce major adverse cardiovascular events by 34% and 45% among individuals with recent acute coronary syndrome. Veradigm collaborates with the American College of Cardiology to deliver vaccination education messaging to cardiology practices using Practice Fusion EHR. The initiative utilizes real-world data to target healthcare providers meeting specific criteria set by ACC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.29%
Tags
none
-
News

New Veradigm Leadership Provides Outlook on Business and Strategy, and Refreshed Financial Estimates for Fiscal 2023

Rhea-AI Summary
Veradigm Inc. (MDRX) Refreshes Estimated Financial Information for Fiscal 2023: Revenue estimated between $608M and $622M, Adjusted EBITDA between $122M and $135M, and Net Cash to exceed $232M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.36%
Tags
earnings
-
News

Veradigm Selects MedAllies as its Qualified Health Information Network™ (QHIN™ ) Partner

Rhea-AI Summary
MedAllies (NASDAQ: MDRX) partners with Veradigm Inc. to improve interoperability and treatment decisions for healthcare providers using Veradigm's EHRs. The partnership aims to provide access to longitudinal patient records, medical history, and medication lists, resulting in better point-of-care decision-making and improved interoperability throughout the healthcare industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
none
News

Veradigm Leadership Team to Present at J.P. Morgan Healthcare Conference

Rhea-AI Summary
Veradigm Inc. (MDRX) to present at the 42nd Annual J.P. Morgan Healthcare Conference, providing an update on business and growth strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
management conferences
-
News

Veradigm Strengthens Award-Winning Revenue Cycle Services Portfolio with Acquisition of Full-Service RCM Company

Rhea-AI Summary
Veradigm Inc. (NASDAQ: MDRX) announces the acquisition of Koha Health, a full-service revenue cycle management company, to enhance its revenue cycle services portfolio in the ambulatory healthcare market. The acquisition brings Musculoskeletal Medicine specialty expertise and the ability to deliver revenue cycle services to ambulatory healthcare provider practices and ambulatory surgical centers utilizing various electronic health record systems.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
acquisition
-
News

Veradigm Inc. Announces that Nasdaq Hearings Panel has Granted its Continued Listing, Pending Return to Compliance with Nasdaq Filing Requirements

Rhea-AI Summary
Veradigm Inc. (NASDAQ: MDRX) received a decision from the Nasdaq Hearings Panel granting its request for continued listing on the Nasdaq Capital Market, subject to compliance with Nasdaq Listing Rule 5250(c)(1) by February 27, 2024, and other conditions. The company remains noncompliant due to the non-filing of its Annual Report on Form 10-K for 2022 and Quarterly Reports on Form 10-Q for 2023. The Panel Decision has no immediate effect on the listing of the company’s common stock on the Nasdaq Global Select Market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.1%
Tags
none
News

Veradigm to Enhance Independent Practice Financial Management with AI for Practice Fusion Billing Services

Rhea-AI Summary
Veradigm Inc. (NASDAQ: MDRX) announced the launch of a conversational AI agent for Practice Fusion Billing Services, aimed at simplifying the billing process and optimizing financial management for independent healthcare providers. The AI, integrated with Microsoft and Zammo.ai software, provides instant conversation responses and feedback, trained in a closed system to generate real-time responses based on a comprehensive billing knowledge base.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
AI

FAQ

What is the current stock price of VERADIGM (MDRX)?

The current stock price of VERADIGM (MDRX) is $10.84 as of November 22, 2024.

What is the market cap of VERADIGM (MDRX)?

The market cap of VERADIGM (MDRX) is approximately 1.2B.

What is Veradigm Inc.?

Veradigm Inc. is a leading provider of healthcare information technology solutions aimed at improving clinical, financial, and operational outcomes.

What type of products does Veradigm offer?

Veradigm offers a range of products including electronic health records (EHR), practice management systems, revenue cycle management, and patient engagement tools.

Why was Veradigm suspended from the NASDAQ Stock Market?

Veradigm was suspended from the NASDAQ Stock Market due to non-compliance with NASDAQ listing rules as of February 29, 2024.

Who replaced Veradigm in the S&P SmallCap 600 index?

Sprinklr Inc. (NYSE: CXM) replaced Veradigm in the S&P SmallCap 600 index effective March 4, 2024.

What distinguishes Veradigm’s healthcare solutions?

Veradigm’s solutions are distinguished by their ability to connect people, places, and data, which empowers caregivers to make better decisions and improve patient care.

Where can I find more information about Veradigm?

More information about Veradigm can be found on their official website, Twitter, YouTube, and their blog.

What is the primary focus of Veradigm’s technology?

Veradigm's technology focuses on creating an open, connected community of health that enhances interoperability and data sharing in healthcare.

How does Veradigm support healthcare providers?

Veradigm supports healthcare providers by offering tools that streamline operations, improve patient outcomes, and facilitate effective decision-making.

Stock MDRX logo
VERADIGM INC

Nasdaq:MDRX

MDRX Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

MDRX Stock Data

1.15B
105.42M
1.12%
23.22%
Health Information Services
Healthcare
Link
United States of America
Chicago